<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03132259</url>
  </required_header>
  <id_info>
    <org_study_id>116/2559</org_study_id>
    <nct_id>NCT03132259</nct_id>
  </id_info>
  <brief_title>Comparative Low and High Dose of Dexmedethomidine in Pituitary Tumor Removal by Transphenoid Approach</brief_title>
  <official_title>Comparative Low and High Dose of Dexmedethomidine Can Stabilize Hemodynamics and Blood Loss in Pituitary Tumor Removal by Transphenoid Approach</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mahidol University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mahidol University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Transnasal transsphenoidal (TNTS) resection of pituitary tumors involves wide fluctuation in
      hemodynamic parameter and causes hypertension and tachycardia due to intense noxious stimuli
      during various stages of surgery. None of routinely used anesthetic agents effectively blunts
      the undesirable hemodynamic responses, and therefore usually there is a need to use increased
      doses of anesthetic agents. Dexmedetomidine (DEX) an α-2 adrenergic receptor agonist, because
      its sympatholytic and antinociceptive properties may ensure optimal intraoperative
      hemodynamic stability during critical moments of surgical manipulation. In addition, DEX
      reduced the anesthetic requirement with rapid recovery at the end of surgery. The main aim of
      the study was to evaluate the effect of DEX on perioperative hemodynamics, anesthetic
      requirements
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      DEX as an anesthetic adjuvant improved hemodynamic stability and decreased anesthetic
      requirements in patients undergoing TNTS resection of pituitary tumor. In addition, DEX
      provided better surgical field exposure conditions and early recovery from anesthesia
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2016</start_date>
  <completion_date type="Anticipated">June 2018</completion_date>
  <primary_completion_date type="Anticipated">May 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Comparative Low and High Dose of Dexmedethomidine in Pituitary Tumor Removal by Transphenoid Approach</measure>
    <time_frame>24 hours</time_frame>
    <description>Low dose is 0.2microgram/kg/hr High dose is 0.5 microgram/kg/hr what is the dose proper and hemodynamic changes. Hemodynamic change means BP is lower than 20% of baseline more than 10minute</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Comparative Low and High Dose of Dexmedethomidine in Pituitary Tumor</measure>
    <time_frame>24 hours</time_frame>
    <description>Low dose is 0.2microgram/kg/hr High dose is 0.5 microgram/kg/hr how much dose blood loss</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">124</enrollment>
  <condition>Pituitary Tumor</condition>
  <arm_group>
    <arm_group_label>High dose dexmedethomidine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>High dose is 0.5 microgram/kg/hr</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low dose dexmedethomidine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Low dose is 0.2 microgram/kg/hr</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>high dose dexmedethomidine</intervention_name>
    <description>Dexmedethomidine continuous drip 0.5 mcg/kg/hr a</description>
    <arm_group_label>High dose dexmedethomidine</arm_group_label>
    <other_name>Precedex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>low dose dexmedethomidine</intervention_name>
    <description>Dexmedethomidine continuous drip 0.2 mcg/kg/hr</description>
    <arm_group_label>Low dose dexmedethomidine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age18-65

          2. ASA 1-2

          3. Elective TNTS resection of Pituitary Tumor

          4. No narcotic before surgery as premedication

          5. Able to Extubate

        Exclusion Criteria:

          1. GCS less than 15

          2. Preoperative Heart Rate less than 50 beat/min

          3. No Beta-Blockers

          4. Pregnant patients

          5. Take any Alpha-Methyldopa, Clonodine, Other Alpha-2 Adrenergic Agonist

          6. Hemodynamic unstable

          7. Systolic BP more than 160mmHg

          8. CAD

          9. Renal insuffuciency

         10. Allergy in dexmedethomidine and opioid

         11. BMI more than 30

         12. Denied consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Saipin Muangman, physician</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mahidol University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Saipin Muangman, physician</last_name>
    <phone>6681 3747786</phone>
    <email>saipinnoolek@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sirinuttakul Akkaworakit, physician</last_name>
    <phone>087- 675-8434</phone>
    <email>gnig.ging@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Faculy of Medicine Siriraj hospital Mahidol University</name>
      <address>
        <city>Bangkok</city>
        <zip>10700</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Saipin Muangman, physician</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <results_reference>
    <citation>Gopalakrishna KN, Dash PK, Chatterjee N, Easwer HV, Ganesamoorthi A. Dexmedetomidine as an Anesthetic Adjuvant in Patients Undergoing Transsphenoidal Resection of Pituitary Tumor. J Neurosurg Anesthesiol. 2015 Jul;27(3):209-15. doi: 10.1097/ANA.0000000000000144.</citation>
    <PMID>25493927</PMID>
  </results_reference>
  <results_reference>
    <citation>Anjum N, Tabish H, Debdas S, Bani HP, Rajat C, Anjana Basu GD. Effects of dexmedetomidine and clonidine as propofol adjuvants on intra-operative hemodynamics and recovery profiles in patients undergoing laparoscopic cholecystectomy: A prospective randomized comparative study. Avicenna J Med. 2015 Jul-Sep;5(3):67-73. doi: 10.4103/2231-0770.160231.</citation>
    <PMID>26229757</PMID>
  </results_reference>
  <results_reference>
    <citation>Polat R, Peker K, Baran I, Bumin Aydın G, Topçu Gülöksüz Ç, Dönmez A. Comparison between dexmedetomidine and remifentanil infusion in emergence agitation during recovery after nasal surgery: A randomized double-blind trial. Anaesthesist. 2015 Oct;64(10):740-6. doi: 10.1007/s00101-015-0077-8. Epub 2015 Sep 2.</citation>
    <PMID>26329913</PMID>
  </results_reference>
  <results_reference>
    <citation>Karwacki Z, Niewiadomski S, Rzaska M, Witkowska M. The effect of bispectral index monitoring on anaesthetic requirements in target-controlled infusion for lumbar microdiscectomy. Anaesthesiol Intensive Ther. 2014 Sep-Oct;46(4):284-8. doi: 10.5603/AIT.2014.0046.</citation>
    <PMID>25293480</PMID>
  </results_reference>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 18, 2016</study_first_submitted>
  <study_first_submitted_qc>April 24, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 27, 2017</study_first_posted>
  <last_update_submitted>May 25, 2017</last_update_submitted>
  <last_update_submitted_qc>May 25, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 30, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mahidol University</investigator_affiliation>
    <investigator_full_name>SMuangman</investigator_full_name>
    <investigator_title>Assisted Professor</investigator_title>
  </responsible_party>
  <keyword>Dexmedethomidine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pituitary Diseases</mesh_term>
    <mesh_term>Pituitary Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

